Table 1.
Antiproliferative activity of the synthesized heterosteroidal compounds.
| Entry | IC50, μM | |||
|---|---|---|---|---|
| Breast cancer | Prostate cancer | |||
| MCF-7 | MDA-MB231 | PC3 | 22Rv1 | |
| 3a | NA | NA | NA | NA |
| 3b | NA | NA | NA | NA |
| 3c | 21.6 ± 2.2 | NA | NA | NA |
| 3d | 12.0 ± 1.4 | NA | NA | NA |
| 3e | 14.9 ± 1.5 | NA | NA | NA |
| 4a | 7.4 ± 0.9 | 14.7 ± 1.6 | 13.5 ± 1.5 | 11.7 ± 1.4 |
| 4b | 11.2 ± 1.4 | 12.2 ± 1.4 | 12.9 ± 1.4 | 9.4 ± 1.0 |
| 4c | 14.8 ± 1.6 | 19.1 ± 2.1 | 22.7 ± 2.4 | 18.1 ± 1.9 |
| Cisplatin (reference drug) | 6.5 ± 0.9 | 14.1 ± 1.7 | 4.9 ± 0.7 | 9.8 ± 1.1 |
NA indicates that the compound does not inhibit the growth by 50% at concentrations lower than 25 μM.